Clinical usefulness of genetic testing for drug toxicity in cancer care: decision-makers’ framing, knowledge and perceptions
To explore the clinical uptake of pharmacogenetic/pharmacogenomic toxicity testing to reduce adverse drug reaction incidences, this paper analyzes data collected through semi-structured face-to-face interviews with clinicians and/or clinician-scientists, primarily in the context of cancer treatment...
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado em: |
Taylor & Francis Group
2020-10-01
|
| Colecção: | New Genetics and Society |
| Assuntos: | |
| Acesso em linha: | http://dx.doi.org/10.1080/14636778.2020.1730165 |
| _version_ | 1827814179422076928 |
|---|---|
| author | Shirley Sun |
| author_facet | Shirley Sun |
| author_sort | Shirley Sun |
| collection | DOAJ |
| description | To explore the clinical uptake of pharmacogenetic/pharmacogenomic toxicity testing to reduce adverse drug reaction incidences, this paper analyzes data collected through semi-structured face-to-face interviews with clinicians and/or clinician-scientists, primarily in the context of cancer treatment in multi-ethnic California (US), Vancouver (Canada) and Singapore. Recurrent themes in the data include the following: first, the scientific evidence for drug-gene interactions is perceived to be generally weak. Second, the primacy of medical treatment’s efficacy over toxicity is the predominant frame through which clinicians consider testing. Third, physicians tailor their decisions according to each patient’s tolerance levels for toxicity. Fourth, racially and ethnically based toxicity risk estimates are a factor shaping the clinical uptake of genetic tests, but they are controversial. These factors contribute to the low clinical uptake of toxicity testing for predictive purposes. We argue that the decision-makers’ framing and perception are additional features to be considered in Hedgecoe’s (2008) “clinical usefulness” framework. |
| first_indexed | 2024-03-11T23:41:48Z |
| format | Article |
| id | doaj.art-9651e37901624c44ab02196f826c7068 |
| institution | Directory Open Access Journal |
| issn | 1463-6778 1469-9915 |
| language | English |
| last_indexed | 2024-03-11T23:41:48Z |
| publishDate | 2020-10-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | New Genetics and Society |
| spelling | doaj.art-9651e37901624c44ab02196f826c70682023-09-19T15:22:18ZengTaylor & Francis GroupNew Genetics and Society1463-67781469-99152020-10-0139435938410.1080/14636778.2020.17301651730165Clinical usefulness of genetic testing for drug toxicity in cancer care: decision-makers’ framing, knowledge and perceptionsShirley Sun0School of Social Sciences, Nanyang Technological UniversityTo explore the clinical uptake of pharmacogenetic/pharmacogenomic toxicity testing to reduce adverse drug reaction incidences, this paper analyzes data collected through semi-structured face-to-face interviews with clinicians and/or clinician-scientists, primarily in the context of cancer treatment in multi-ethnic California (US), Vancouver (Canada) and Singapore. Recurrent themes in the data include the following: first, the scientific evidence for drug-gene interactions is perceived to be generally weak. Second, the primacy of medical treatment’s efficacy over toxicity is the predominant frame through which clinicians consider testing. Third, physicians tailor their decisions according to each patient’s tolerance levels for toxicity. Fourth, racially and ethnically based toxicity risk estimates are a factor shaping the clinical uptake of genetic tests, but they are controversial. These factors contribute to the low clinical uptake of toxicity testing for predictive purposes. We argue that the decision-makers’ framing and perception are additional features to be considered in Hedgecoe’s (2008) “clinical usefulness” framework.http://dx.doi.org/10.1080/14636778.2020.1730165toxicitygenetic testingclinical uptakerace/ethnicityframingperceptionsevidence-based precision medicine |
| spellingShingle | Shirley Sun Clinical usefulness of genetic testing for drug toxicity in cancer care: decision-makers’ framing, knowledge and perceptions New Genetics and Society toxicity genetic testing clinical uptake race/ethnicity framing perceptions evidence-based precision medicine |
| title | Clinical usefulness of genetic testing for drug toxicity in cancer care: decision-makers’ framing, knowledge and perceptions |
| title_full | Clinical usefulness of genetic testing for drug toxicity in cancer care: decision-makers’ framing, knowledge and perceptions |
| title_fullStr | Clinical usefulness of genetic testing for drug toxicity in cancer care: decision-makers’ framing, knowledge and perceptions |
| title_full_unstemmed | Clinical usefulness of genetic testing for drug toxicity in cancer care: decision-makers’ framing, knowledge and perceptions |
| title_short | Clinical usefulness of genetic testing for drug toxicity in cancer care: decision-makers’ framing, knowledge and perceptions |
| title_sort | clinical usefulness of genetic testing for drug toxicity in cancer care decision makers framing knowledge and perceptions |
| topic | toxicity genetic testing clinical uptake race/ethnicity framing perceptions evidence-based precision medicine |
| url | http://dx.doi.org/10.1080/14636778.2020.1730165 |
| work_keys_str_mv | AT shirleysun clinicalusefulnessofgenetictestingfordrugtoxicityincancercaredecisionmakersframingknowledgeandperceptions |